Akeso's five drugs secure full NRDL coverage

Akeso, Inc. (Akeso) has announced that all approved indications for its five marketed innovative drugs have been included in China's most recent National Reimbursement Drug List (NRDL) for 2025. This inclusion, effective January 1, 2026, covers cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), penpulimab (PD-1), ebronucimab (PCSK9), and ebdarokimab (IL-12/IL-23).

The NRDL update for cadonilimab renews coverage for recurrent or metastatic cervical cancer and adds new indications for first-line treatment of locally advanced, unresectable, or metastatic gastric/gastroesophageal junction adenocarcinoma, and persistent, recurrent, or metastatic cervical cancer. Ivonescimab's coverage for non-squamous non-small cell lung cancer (NSCLC) post-EGFR TKI progression is renewed, with a new indication for first-line treatment of PD-L1-positive NSCLC.

Penpulimab, co-developed with Sino Biopharmaceutical Limited, is included for classical Hodgkin lymphoma, squamous NSCLC, and nasopharyngeal carcinoma. Ebronucimab is covered for primary hypercholesterolemia, mixed hyperlipidemia, and familial hypercholesterolaemia, while ebdarokimab is included for moderate to severe plaque psoriasis.